Summary:
The purpose of this study is to evaluate the effectiveness and safety of an investigational compound for Major Depressive Disorder. The study consists of a 5 week outpatient study treatment period, followed by a one week safety follow up period. All procedures and study visits will take place at CBH Health located in Gaithersburg, MD.
• Male or Female, Ages 18-65
• Diagnosis of Major Depressive Disorder and currently experiencing a Major Depressive Episode
• Be in good physical health as ascertained by medical history, physical examination, and clinical laboratory evaluations
• History of bipolar disorder, schizophrenia, or schizoaffective disorder is exclusionary.
• No seizure disorder, strokes or tumor
• Current diagnosis of substance abuse or within past 6 months is exclusionary
• Current sucidal ideation or a suicide attempt within the past 2 years is exclusionary
Qualified Participants May Receive:
Compensation will be provided.